drugset
drugset / Trial / NCT05007418

Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma

NCT05007418 ↗

Phase 1 Unknown 54 enrolled Sorrento Therapeutics, Inc.
NaSequentialOpen-labelTreatment

Summary

This is a phase 1b, open-label, dose-escalation study of STI-1492 administered by a single intravenous infusion in subjects with relapsed or refractory multiple myeloma.

Timeline

Start
2022-10-01
Primary completion
2025-12
Completion
2026-02

Drugs

EvaluationDrugModalityDoseRoute
Subject STI-1492 Cell therapy 100000 cells/kg Intravenous
Subject STI-1492 Cell therapy 500000 cells/kg Intravenous
Subject STI-1492 Cell therapy 1e+06 cells/kg Intravenous
Subject STI-1492 Cell therapy 3e+06 cells/kg Intravenous

Indications

plasma cell myeloma